Literature DB >> 26774286

FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4.

Qiang Zhang1, David Karnak1, Mingjia Tan1, Theodore S Lawrence1, Meredith A Morgan2, Yi Sun3.   

Abstract

FBXW7 is a haploinsufficient tumor suppressor with loss-of-function mutations occurring in human cancers. FBXW7 inactivation causes genomic instability, but the mechanism remains elusive. Here we show that FBXW7 facilitates nonhomologous end-joining (NHEJ) repair and that FBXW7 depletion causes radiosensitization. In response to ionizing radiation, ATM phosphorylates FBXW7 at serine 26 to recruit it to DNA double-strand break (DSB) sites, whereas activated DNA-PKcs phosphorylates XRCC4 at serines 325/326, which promotes binding of XRCC4 to FBXW7. SCF(FBXW7) E3 ligase then promotes polyubiquitylation of XRCC4 at lysine 296 via lysine 63 linkage for enhanced association with the Ku70/80 complex to facilitate NHEJ repair. Consistent with these findings, a small-molecule inhibitor that abrogates XRCC4 polyubiquitylation reduces NHEJ repair. Our study demonstrates one mechanism by which FBXW7 contributes to genome integrity and implies that inactivated FBXW7 in human cancers could be a strategy for increasing the efficacy of radiotherapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26774286      PMCID: PMC4744117          DOI: 10.1016/j.molcel.2015.12.010

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  67 in total

1.  Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV.

Authors:  S E Critchlow; R P Bowater; S P Jackson
Journal:  Curr Biol       Date:  1997-08-01       Impact factor: 10.834

2.  Lysine 271 but not lysine 210 of XRCC4 is required for the nuclear localization of XRCC4 and DNA ligase IV.

Authors:  Mikoto Fukuchi; Rujira Wanotayan; Sicheng Liu; Shoji Imamichi; Mukesh Kumar Sharma; Yoshihisa Matsumoto
Journal:  Biochem Biophys Res Commun       Date:  2015-04-28       Impact factor: 3.575

Review 3.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Authors:  Yongchao Zhao; Meredith A Morgan; Yi Sun
Journal:  Antioxid Redox Signal       Date:  2014-02-20       Impact factor: 8.401

4.  Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair.

Authors:  R M Hofmann; C M Pickart
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

5.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Authors:  Jian-Hua Mao; Jesus Perez-Losada; Di Wu; Reyno Delrosario; Ryosuke Tsunematsu; Keiichi I Nakayama; Ken Brown; Sheila Bryson; Allan Balmain
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

6.  DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair.

Authors:  Takashi Ochi; Andrew N Blackford; Julia Coates; Satpal Jhujh; Shahid Mehmood; Naoka Tamura; Jon Travers; Qian Wu; Viji M Draviam; Carol V Robinson; Tom L Blundell; Stephen P Jackson
Journal:  Science       Date:  2015-01-09       Impact factor: 47.728

7.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 8.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206

9.  Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Authors:  Yan Zhao; Huw D Thomas; Michael A Batey; Ian G Cowell; Caroline J Richardson; Roger J Griffin; A Hilary Calvert; David R Newell; Graeme C M Smith; Nicola J Curtin
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 10.  The clinical impact of deficiency in DNA non-homologous end-joining.

Authors:  Lisa Woodbine; Andrew R Gennery; Penny A Jeggo
Journal:  DNA Repair (Amst)       Date:  2014-03-11
View more
  53 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

2.  LSD1 destabilizes FBXW7 and abrogates FBXW7 functions independent of its demethylase activity.

Authors:  Huiyin Lan; Mingjia Tan; Qiang Zhang; Fei Yang; Siyuan Wang; Hua Li; Xiufang Xiong; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-31       Impact factor: 11.205

Review 3.  Ubiquitination at the interface of tumor viruses and DNA damage responses.

Authors:  Joseph M Dybas; Christin Herrmann; Matthew D Weitzman
Journal:  Curr Opin Virol       Date:  2018-09-24       Impact factor: 7.090

4.  HIF-1α promotes the keloid development through the activation of TGF-β/Smad and TLR4/MyD88/NF-κB pathways.

Authors:  Rui Lei; Jian Li; Feng Liu; Weihan Li; Shizhen Zhang; Yang Wang; Xi Chu; Jinghong Xu
Journal:  Cell Cycle       Date:  2019-10-23       Impact factor: 4.534

Review 5.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

6.  Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer.

Authors:  Yuli Wang; Pengju Zhang; Yunshan Wang; Panpan Zhan; Chunyan Liu; Jian-Hua Mao; Guangwei Wei
Journal:  Cancer Res       Date:  2017-02-16       Impact factor: 12.701

7.  Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer.

Authors:  Jason K Douglas; Rose E Callahan; Zachary A Hothem; Craig S Cousineau; Samer Kawak; Bryan J Thibodeau; Shelli Bergeron; Wei Li; Claire E Peeples; Harry J Wasvary
Journal:  Mol Cell Oncol       Date:  2020-03-02

8.  TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination.

Authors:  Benjamin C Chandler; Leah Moubadder; Cassandra L Ritter; Meilan Liu; Meleah Cameron; Kari Wilder-Romans; Amanda Zhang; Andrea M Pesch; Anna R Michmerhuizen; Nicole Hirsh; Marlie Androsiglio; Tanner Ward; Eric Olsen; Yashar S Niknafs; Sofia Merajver; Dafydd G Thomas; Powel H Brown; Theodore S Lawrence; Shyam Nyati; Lori J Pierce; Arul Chinnaiyan; Corey Speers
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 9.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

10.  Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.

Authors:  Qiyin Zhou; Hua Li; Yuanyuan Li; Mingjia Tan; Shaohua Fan; Cong Cao; Feilong Meng; Ling Zhu; Lili Zhao; Min-Xin Guan; Hongchuan Jin; Yi Sun
Journal:  JCI Insight       Date:  2019-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.